"We continue to expect that Medicenna will release a major update on the $MDNA ABILITY -1 trial – mono therapy and combo (+pembrolizumab) expansion cohorts – before the end of this year " Bloom Burton has a $8.40 CAD 12 month target in its latest October research report 👏

On top of that, an Italian group is backing a new trial that uses MDNA11 before surgery in high-risk melanoma, and their next drug MDNA113 is moving toward first-in-human studies. With cash into at least mid-2026, Dec 10 should give a clearer view of how big this story can get.

That's a seriously bullish candle for $LIB.V.🔥 Nice bounce after finding strong support at the prior high. 4.7M shorts...

Lisäsin annoksen syöpälääkettä sijoitussalkkuuni. Medicenna Therapeutics $MDNAF kehittää seuraavan sukupolven syöpälääkkeitä ja uskon tässä olevan nollaa suurempi todennäköisyys sijoitukseni moninkertaistumiseen. Lue idea kokonaisuudessaan täältä👇 https://t.co/yEQgK7Bwuz

https://t.co/UgGttC9PPK $MDNA $MDNAF

"We continue to expect that Medicenna will release a major update on the $MDNA ABILITY -1 trial – mono therapy and combo (+pembrolizumab) expansion cohorts – before the end of this year " Bloom Burton has a $8.40 CAD 12 month target in its latest October research report 👏

Upcoming catalyst for $MDNA.TO 👇 On Dec 10 Medicenna will present updated MDNA11 data at the ESMO Immuno Oncology meeting. MDNA11 is their long-acting IL-2 drug being tested in hard-to-treat solid tumors that already failed standard immunotherapy. https://t.co/BZj19oGveZ

$MDNA $MDNAF

@Gantosj I have a feeling the results will be freaking amazing! Fahar sounded super upbeat at the Planet Microcap conference a month ago $MDNA $MDNAF

$MDNAF $MDNA.to bouncing up & breaking out the US$1.20resistance line Investors are waiting patiently for the data release at #ESMO-IO this Wed 12/10

https://t.co/U3kGmmwhE3 $MDNA $MDNAF Medicenna's MDNA11 is showing remarkable activity in end-stage patients who've already failed Keytruda - including complete tumor disappearances and durable responses lasting over a year after stopping treatment

https://t.co/U3kGmmwhE3 $MDNA $MDNAF Medicenna's MDNA11 is showing remarkable activity in end-stage patients who've already failed Keytruda - including complete tumor disappearances and durable responses lasting over a year after stopping treatment

https://t.co/On67m9uali $MDNA $MDNAF The science behind MDNA11. 5 days away until the big mono and combo reveal 🤯

This is such exciting news! It’s technical… but it may be significant for many people needing hope. $MDNA 👇

https://t.co/On67m9uali $MDNA $MDNAF The science behind MDNA11. 5 days away until the big mono and combo reveal 🤯

$MDNA $MDNAF MDNA11’S CORE INNOVATION: ONLY THE GOOD PATHWAY TURNS ON MDNA11 is β/γ-selective, which means: CD8+ T cells = ON NK cells = ON Tregs (CD25-positive) = OFF https://t.co/bykqJ0iXEO

"We are eagerly anticipating the upcoming clinical update for MDNA11 from the global phase 1/2 ABILITY-1 clinical trial to demonstrate its potential as a best-in-class IL-2 therapy" Fahar Merchant CEO Medicenna Therapeutics $MDNA $MDNAF

https://t.co/BF1AMX674S This explains everything about the potentially best in class MDNA11 IL2 drug. The lead investigator Dr. Arash Yavari for the MDNA11 trial talks about it in this video Cant wait for the big reveal of combo and mono 115 patients globally $MDNA $MDNAF

https://t.co/BF1AMX674S This explains everything about the potentially best in class MDNA11 IL2 drug. The lead investigator Dr. Arash Yavari for the MDNA11 trial talks about it in this video Cant wait for the big reveal of combo and mono 115 patients globally $MDNA $MDNAF

"We are eagerly anticipating the upcoming clinical update for MDNA11 from the global phase 1/2 ABILITY-1 clinical trial to demonstrate its potential as a best-in-class IL-2 therapy" Fahar Merchant CEO Medicenna Therapeutics $MDNA $MDNAF